from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2Q2PZRC on October 30, 2018 at 04:52PM
While some companies are working to implement new plans to pull down drug prices, some which fail to consider “a wide variety of factors in value assessment” could spell access troubles for patients in need, according to an article published on Journal of Clinical Pathways.
The article takes a look at separate programs launched by CVS Health and the New York State Board responsible for Medicaid. Both programs, according to the article, restrict access to high-cost treatments based on cost-effectiveness measures by the Institute for Clinical and Economic Review (ICER).
“It is important to follow these developments, as future clinical pathways may follow a similar lead in providing cost-effective treatment options based on QALY, with some therapies not being included,” the authors write.